Cargando…

Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial

Introduction This X-VeRT (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) substudy evaluated the effects of treatment with rivaroxaban or a vitamin-K antagonist (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirchhof, Paulus, Ezekowitz, Michael D., Purmah, Yanish, Schiffer, Sonja, Meng, Isabelle L., Camm, A. John, Hohnloser, Stefan H., Schulz, Anke, Wosnitza, Melanie, Cappato, Riccardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978177/ https://www.ncbi.nlm.nih.gov/pubmed/31984306 http://dx.doi.org/10.1055/s-0040-1701206

Ejemplares similares

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial
por: Hohnloser, Stefan H., et al.
Publicado: (2016)

The IL-10(GFP) (VeRT-X) mouse strain is not suitable for the detection of IL-10 production by granulocytes during lung inflammation
por: Özkan, Müge, et al.
Publicado: (2021)

Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe
por: Schnabel, Renate B., et al.
Publicado: (2018)

Detection of unknown atrial fibrillation by prolonged ECG monitoring in an all-comer patient cohort and association with clinical and Holter variables
por: Jawad-Ul-Qamar, Muhammad, et al.
Publicado: (2020)

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
por: Camm, A John, et al.
Publicado: (2014)

Verte desnudo
Publicado: (1992)

Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study
por: Camm, A. John, et al.
Publicado: (2020)

Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis
por: Vamos, Mate, et al.
Publicado: (2016)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Para verte reír
por: Mond, F., 1941-
Publicado: (1983)

La jument verte /
por: Aymé, Marcel, 1902-1967
Publicado: (1933)

Instant Vert.x
por: Scarduzio, Simone
Publicado: (2013)

Vert.x in Action
por: Ponge, Julien
Publicado: (2020)

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
por: Camm, A. John, et al.
Publicado: (2016)

Para verte mejor, : América Latina
por: Gasparini, Paolo
Publicado: (2009)

Feu vert pour ALICE
Publicado: (1997)

Feu vert pour PEP
Publicado: (1976)

Hasta no verte Jesús mío /
por: Poniatowska, Elena
Publicado: (1984)

Hasta no verte Jesús mío
por: Poniatowska, Elena
Publicado: (1986)

Hasta no verte, Jesus mío
por: Poniatowska, Elena
Publicado: (1969)

Hasta no verte Jesús mío /
por: Poniatowska, Elena
Publicado: (2014)

Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation
por: Chua, Winnie, et al.
Publicado: (2019)

Les vertes collines d'Afrique
por: Hemingway, Ernest, 1899-1961
Publicado: (1949)

A Graphical Solution for Espaces Verts
por: Skelton, K
Publicado: (1999)

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation
por: Burghaus, Rolf, et al.
Publicado: (2011)

The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence
por: Schiffer, Sonja, et al.
Publicado: (2023)

Feu vert pour un CDC 7600
Publicado: (1970)

Daresbury : Feu vert pour le NSF
Publicado: (1974)

Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death
por: Brady, Paul F., et al.
Publicado: (2022)

Feu vert pour le L.E.P.
Publicado: (1981)

Computational identification of adaptive mutants using the VERT system
por: Winkler, James, et al.
Publicado: (2012)

Le Conseil fédéral donne son feu vert
Publicado: (2009)

InVERT molding for scalable control of tissue microarchitecture
por: Stevens, KR, et al.
Publicado: (2013)

Routine coagulation test abnormalities caused by rivaroxaban: A case report
por: Song, Zikai, et al.
Publicado: (2018)

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
por: Kim, Paul Y., et al.
Publicado: (2018)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Association between hypocalcemia and rivaroxaban in coagulation disorders: a case report
por: Pos, Alexandre Mio, et al.
Publicado: (2020)

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
por: Cappato, Riccardo, et al.
Publicado: (2015)

Rutherford : Feu vert pour la source de neutrons
Publicado: (1977)

Feu vert pour le supercollisionneur des Etats-Unis
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_dfsk0va30in05bdlq4bk3a7oqh